Chronic Bacterial Prostatitis When T. vaginalis Is the Causative Pathogen
Clinical Scenario
In a subset of chronic bacterial prostatitis (CBP) cases, Trichomonas vaginalis is identified as the causative pathogen. This finding directly shapes the treatment decision, requiring a targeted approach directed at the confirmed organism rather than standard antibacterial coverage.
Treatment Approach
When T. vaginalis is confirmed as the causative pathogen in CBP, antiprotozoal antimicrobial therapy is indicated as the first-line intervention. The complete agent selection, dosing schedule, and clinical decision points are detailed in the full structured protocol.
Full regimen details available in the protocol below.
Treatment Goals
- Cessation of prostatitis symptoms
- Eradication of T. vaginalis
References
- Prescribe metronidazole in patients with T. vaginalis CBP.
- Metronidazole treatment is indicated in patients with T. vaginalis infections.
- Metronidazole 500mg three times daily for fourteen days was found to be efficient for eradication in 93.3% of patients with T. vaginalis CBP.
- In asymptomatic post-treatment patients, routine urinalysis and/or urine culture is not mandatory as there are no validated tests of cure for bacterial prostatitis except for cessation of symptoms.
View source ↗